Evaluation of cancer chemopreventive agents using clones derived from a human prostate cancer cell line

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4177-4183

  Ware, Jeffrey H ^a   Zhou, Zhaozong ^a   Kopelovich, Levy ^b   Kennedy, Ann R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemopreventive agents; LNCaP; Prostate cancer cell clones

Indexed keywords

7 BETA FLUASTERONE; ALITRETINOIN; FLUASTERONE; SELENOMETHIONINE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CANCER CELL; CELL CLONING; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33845943434     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parker SL et al: Cancer statistics, 1997. Ca Cancer J Clin 47: 5-27, 1997.
2. Tominaga S: Cancer incidence in Japanese in Japan, Hawaii, and Western United States. Natl Cancer Inst Monogr 69: 83-92, 1985.
3. Dunn JE: Cancer epidemiology in populations of the United States with emphasis on Hawaii and California and Japan. Cancer Res 35: 3240-3245, 1975.
4. Boone CW, Steele VE and Kelloff GJ: Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res 267: 251-255, 1992.
5. Schwartz AG and Pashko LL: Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Suppl. 22: 210-217, 1995.
6. El-Bayoumy K et al: Chemoprevention of cancer by organoselenium compounds. Biochem Suppl 22: 92-100, 1995.
7. Mitchell MF et al: Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer 76: 1956-1977, 1995.
8. Kelloff GJ et al: Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl. 26: 54-71, 1996.
9. Kelloff GJ et al: New agents for cancer chemoprevention. J Cell Biochem Suppl. 26: 1-28, 1996.
10. Miller WH Jr: The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 83: 1471-1482, 1998.
11. Wan XS et al: In vitro evaluation of chemopreventive agents using cultured human prostate epithelial cells. Oncology Reports 10: 2009-2014, 2003.
12. Wan XS et al: Establishment and characterization of sublines of LNCaP human prostate cancer cells. Oncology Reports 10: 1569-1575, 2003.
13. Keepers YP et al: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897-900, 1991.
14. Basolo F et al: Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinogenesis 4: 25-35, 1991.
15. Calaf G and Russo J: Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14: 483-492, 1993.
16. Barrett JC: Cell culture models of multistep Carcinogenesis. IARC Sci. Publications 58: 181-202, 1985.
17. Freedman DA and Navidi WC: Multistage models for carcinogenesis. Environ. Health Persp 81: 169-188, 1989.
18. Cook P, Doll R and Fellingham SA: A mathematical model for the age distribution of cancer in man. Intl J Cancer 4: 93-112, 1969.
19. Manton KG and Stallard E: Bioactuarial models of national mortality time series data. Hlth Care Fin Rev 3: 89-106, 1982.
20. Manton KG, Malker H and Malker B: A comparison of temporal changes in U.S. and Swedish lung cancer 1950-51 to 1981-82. J. Natl. Cancer Inst 77: 665-675, 1986.
21. Moolgavkar SH: A population perspective on multistage carcinogenesis. Princess Takamatsu Symposia 22: 381-391, 1991.
22. Moolgavkar SH and Luebeck EG: Multistage carcinogenesis: population-based model for colon cancer. Journal of the National Cancer Institute 84: 610-618, 1992.
23. Anzano MA et al: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54: 4614-4617, 1994.
24. Zheng Y et al: Prevention of retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis 18: 2119-2125, 1997.
25. Esquenet M et al: Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25- dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28: 182-194, 1996.
26. Toma S et al: Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 18: 935-942, 1998.
27. Orner GA et al: Comparison of the enhancing effects of dehydroepiandrosterone with the structural analog 16 alpha-fluoro-5-androsten- 17-one on aflatoxin B1 hepatocarcinogenesis in rainbow trout. Fund Appl Toxicol 34: 132-140, 1996.
28. Clark LC et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 276: 1957-1963, 1996.
29. Ip C: Differential effect of dietary methionine on the biopotency of selenomethionine and selenite in cancer chemoprevention. J Natl Cancer Inst 80: 258-262, 1988.
30. Redman C et al: Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 125: 103-110, 1998.
31. Fujiwara T and Horikoshi H: Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 67: 2405-2416, 2000.
32. Mehta RG et al: A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92: 418-423, 2000.